Boston Pharmaceuticals Achieves Phase 2 Success with Efimosfermin Alfa for MASH Treatment, Paving Way for Pivotal Trials
Phase 2 Success:
Boston Pharmaceuticals has announced positive Phase 2 data for efimosfermin alfa (BOS-580) in treating metabolic dysfunction-associated steatohepatitis (MASH), demonstrating significant improvements in fibrosis and MASH resolution without worsening15.
Treatment Details:
Efimosfermin alfa is a long-acting, once-monthly FGF21 analogue aimed at treating MASH, a growing global epidemic fueled by increasing obesity and metabolic disease2.
Clinical Benefits:
The Phase 2a trial showed reductions in markers of liver injury and fibrosis, and improvements in metabolic health markers with once-monthly dosing of efimosfermin23.
Low Immunogenicity:
The drug has demonstrated low immunogenicity rates, which is crucial for sustained efficacy over time, distinguishing it from other FGF21 analogues3.
Pivotal Trials:
Following the Phase 2 success, Boston Pharmaceuticals is positioned to advance efimosfermin alfa into pivotal trials, following in the footsteps of companies like Akero and 89bio45.
Presentation:
The Phase 2 biopsy results will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024, highlighting the drug's potential as a best-in-class option for MASH patients5.
Sources:
1. https://www.biospace.com/press-releases/boston-pharmaceuticals-to-announce-positive-phase-2-data-on-efimosfermin-alfa-bos-580-in-f2-f3-mash-during-late-breaking-oral-presentation-at-aasld-2024-the-liver-meeting
2. https://www.bostonpharmaceuticals.com/pipeline
3. https://www.businesswire.com/news/home/20240105286712/en/Boston-Pharmaceuticals-Presents-Data-at-NASH-TAG-2024-Demonstrating-Low-Immunogenicity-Over-Time-With-Long-acting-FGF21-Analogue-BOS-580-for-MASH
4. https://www.fiercebiotech.com/biotech/boston-hits-phase-2-mash-goal-positioning-monthly-prospect-follow-akero-89bio-pivotal
5. https://www.businesswire.com/news/home/20241016942643/en/Boston-Pharmaceuticals-to-Present-Phase-2-Biopsy-Results-for-Long-Acting-Once-Monthly-FGF21-Analogue-Efimosfermin-Alfa-BOS-580-in-F2-and-F3-MASH-in-Late-Breaking-Oral-Presentation-at-AASLD-The-Liver-Meeting%C2%AE-2024